Phase I Clinical trial of personalized peptide vaccine in combination with humanized anti-IL6 receptor monoclonal antibody for refractory colorectal cancer patients - Clinical trial of peptide vaccine in combination with anti-IL6 receptor antibody for refractory colorectal cancer patients

Kurume University Cancer Vaccine Center0 个研究点目标入组 18 人开始时间: 2012年3月13日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•The following patients must be excluded: 1) Patients with severe underlying diseases (active and severe infectious diseases, activa tuberculosis, circulatory diseases, respiratory diseases, renal diseases, immunodeficiency, disturbance of coagulation, etc). 2) Patients with active interstitial pneumonia or its past history. 3) Patients with active double cancer [synchronic double cancer or asynchronous double cancer with no more than 5-year disease-free period, excluding carcinoma in situ (lesions equal to intraepithelial or intramucosal cancer) judged to have been cured by local treatment]. 4) Patients with the past history of severe allergic reactions. 5) Patients with Castleman's disease, rheumatoid arthritis, or juvenile idiopathic arthritis or with the past history of them. 6) Patients with the past history of previous tretamnet with anti-IL-6 receptor antibody. 7) Patients with the past history of previous tretament with personalized peptide vaccine developed by Kurume University. 8) Pregnant, nursing, or who wants pregnancy. Patients with no acceptance of effective contraception during and for at least 70 days after study participation. 9) Patients with other inappropriate conditions for enrollment judged by the clinicians.

发起方

Kurume University Cancer Vaccine Center